SCHEMBL1507927

SCHEMBL1507927

COP(=O)(OC)C(OCC(C)C)(c1ccc(F)cc1)c1ccccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.37
CYP3A4 P08684 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KCNE1 P15382 1/20 0.36
KCNQ1 P51787 1/20 0.36
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
MLNR O43193 1/20 0.30
NR1I2 O75469 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
TBXA2R P21731 1/20 0.30
CCKBR P32239 1/20 0.30
OPRK1 P41145 1/20 0.30
SLC6A3 Q01959 1/20 0.30
KCNH2 Q12809 1/20 0.30
NR1H4 Q96RI1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507930 0.81 KCNN4 (0.40) KCNN4CYP3A4MEN1KMT2ALMNA
SCHEMBL1508011 0.74 KCNN4 (0.45) KCNN4CYP3A4MEN1KMT2ALMNA
SCHEMBL1508116 0.71 NPC1 (0.34) KCNN4LMNA
SCHEMBL14066331 0.69 KCNN4 (0.40) KCNN4LMNASMN1; SMN2KCNE1KCNQ1
SCHEMBL1508145 0.68 KCNN4 (0.40) KCNN4SMN1; SMN2KCNE1KCNQ1HDAC6
SCHEMBL1508241 0.65 NPC1 (0.33) KCNN4CYP3A4MEN1KMT2ALMNA
SCHEMBL1507954 0.64 KCNN4 (0.36) KCNN4MEN1KMT2ALMNASMN1; SMN2
SCHEMBL781360 0.62 KCNN4 (0.44) KCNN4KCNE1KCNQ1MLNRNR1I2
SCHEMBL1508072 0.62 KCNN4 (0.43) KCNN4CYP3A4KCNE1KCNQ1MLNR
SCHEMBL777579 0.62 KCNN4 (0.50) KCNN4KCNE1KCNQ1HDAC6MLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KCNN4 48/4885CYP3A4 2918/4885MEN1 3688/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KCNN4 48/4885CYP3A4 2918/4885MEN1 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.